NOT FOR HUMAN CONSUMPTION

AHK-Cu, also known as Copper Tripeptide-1, is a naturally occurring copper-binding tripeptide with the amino-acid sequence Gly-His-Lys (GHK) complexed with Cu²⁺. In human physiology, GHK-Cu is released during tissue injury and remodeling and functions as a signal peptide that coordinates repair, regeneration, and inflammation control.

Regulatory context:
AHK-Cu is widely used in cosmetic, dermatologic, and research applications. It is not FDA-approved as a drug, but it is one of the most extensively studied bioactive peptides in skin biology.

2) Biological rationale

Copper is an essential trace element for:

• collagen and elastin cross-linking (lysyl oxidase),

• angiogenesis,

• antioxidant defense (superoxide dismutase),

• cellular energy metabolism.

The GHK peptide acts as a targeted copper delivery system, ensuring copper reaches sites of tissue repair while avoiding free-copper toxicity. Together, the complex functions as a master regulator of tissue homeostasis.

3) Molecular mechanism of action

3.1 Gene-expression modulation

AHK-Cu is notable for its ability to influence hundreds to thousands of genes involved in:

• extracellular matrix (ECM) synthesis,

• inflammation suppression,

• antioxidant pathways,

• cell growth and differentiation.

Transcriptomic analyses suggest GHK-Cu upregulates regenerative genes while downregulating pro-inflammatory and fibrotic genes, a rare profile among cosmetic peptides.

3.2 Skin and connective-tissue effects

3.3 Hair follicle biology

AHK-Cu supports hair follicle health by:

• promoting dermal papilla cell survival,

• improving follicular angiogenesis,

• counteracting inflammation-driven miniaturization.

This has led to its inclusion in hair-growth and scalp-repair formulations.

4) Pharmacokinetics and delivery considerations

• Topical delivery: primary and best-studied route (serums, creams, foams).

• Skin penetration: enhanced by copper chelation and appropriate vehicle formulation.

• Stability: copper-bound form is significantly more biologically active than free GHK.

Injectable and systemic use remains research-only and is not supported by approved clinical pharmacology data.

5) Evidence base

5.1 Preclinical and mechanistic evidence (strong)

• Robust in-vitro fibroblast and keratinocyte studies show increased ECM production and improved wound-healing kinetics.

• Gene-expression studies demonstrate broad regenerative signaling unmatched by most cosmetic actives.

5.2 Human clinical and applied evidence (moderate)

Human studies and long-term cosmetic use support improvements in:

• skin firmness and elasticity,

• fine lines and wrinkles,

• wound healing and scar appearance,

• post-procedure recovery (laser, microneedling, chemical peels).

While many studies are small or formulation-dependent, the totality of evidence across decades is unusually strong for a non-drug peptide.

6) Practical benefits (evidence-weighted)

7) Safety and tolerability

AHK-Cu is generally well tolerated, especially topically.

Potential issues:

• Transient blue coloration on skin if over-concentrated

• Mild irritation in sensitive individuals

• Copper sensitivity is rare but possible

Not recommended:

• For use on active infections

• In formulations exceeding physiologically reasonable copper concentrations

8) Formulation considerations

• Typical cosmetic concentrations: 0.01–0.05% active peptide

• pH-sensitive; stability depends on formulation chemistry

• Often synergistic with:

  • hyaluronic acid,

  • niacinamide,

  • growth-factor-supporting actives

• Should not be layered immediately with strong acids or chelators that disrupt copper binding

9) Comparative positioning